GlucoTrack announces increase sensory longevity for CBGM

Glucotrack and The Technology Partnership, TTP, announced the completion of computational modeling for Glucotrack’s implantable Continuous Blood Glucose Monitor, CBGM, suggesting sensor longevity beyond three years, a year longer than the Company previously announced. Glucotrack has engaged TTP for the development of computational modeling, which addresses enzyme longevity for use in long-term implantable electrochemical sensors. “TTP is well versed in supporting clients with creating breakthrough medical technology solutions,” said Paul Goode, PhD, CEO of Glucotrack. “This collaboration has enhanced our development program, and the projected increase in sensor longevity to beyond three years further demonstrates that our technology is truly differentiated in the glucose monitoring space. This achievement doesn’t change our commercialization timing but instead paves the way for future generations of our system, which will be a truly long-term CBGM to people living every day with diabetes.”